4DX

8.62%

53.0¢ 4dmedical limited

Agreed. But these are inherent risks faced by every company.

First 19 Last

Share
Profile

Follow
KainCarver

2,264 Posts.

685

11/12/21

14:50

Post #: 58232033
Share

Originally posted by chibba123 ↑

Of course a US contract is baked in, it's all AF talks about!!!
You do know that 4DX has a market cap of $250m (even more when fully diluted) on no operational revenue (or insignificant at best). That's a pretty high valuation in my mind. The US opportunity is the only thing keeping this stock from going down to 10c.

Here's why it's not a multi-billion dollar company now based on where it could be if the tech gets fully adopted, off the top of my head:
1. Most (probably 99%+) institutional funds won't touch this type of stock with a barge pole due to no reported revenue (let alone profit), no matter how good the tech is. It won't pass the filters. They like to see money coming in the door before they jump on board. At the moment 4DX is a plaything of retail mugs like you and I, and day traders who couldn't give a stuff about fundamentals.
2. EXECUTION RISK! What happens if they don't sign the deals that would make them grow at the pace expected. What if the deal flow is slower. What if there's some other tech that's just as amazing that you don't know about? What happens if AF is hit by a car next week?
3. Time value of money. We're not expected to get significant revenue for a few years yet. The medical industry is a slow moving beast. A dollar now is worth more than a dollar in a few years. Funds generally operate on a discount rate of 8%ish to my knowledge.
4. There are other high risk opportunities around for retail investors (i.e. competition for funds).
5. EXECUTION RISK! Did I say that one already?
6. 4DX isn't even that well known among retail investors. How many of your friends have heard of it (and not because you told them). Look at how many people post on this forum (or even view it). I've never seen it mentioned on reddit.
7. EXECUTION RISK!

Expand

Agreed. But these are inherent risks faced by every company.

4DX Price at posting: $1.19 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 16 more messages in this thread...

First 19 Last

Add 4DX (ASX) to my watchlist

(20min delay)
Last 53.0¢		Change -0.050(8.62%)		Mkt cap ! $217.5M

Open	High	Low	Value	Volume
57.5¢	57.5¢	52.5¢	$945.4K	1.730M

Buyers (Bids)

No.	Vol.	Price($)
2	151700	53.0¢

Sellers (Offers)

Price($)	Vol.	No.
54.0¢	55780	3

View Market Depth

No.	Vol.	Price($)
2	151700	0.530
2	11096	0.525
8	115324	0.520
1	6000	0.515
5	34950	0.510

Price($)	Vol.	No.
0.540	55780	3
0.545	35619	2
0.555	6200	1
0.560	45165	3
0.570	25000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

4DX (ASX) Chart

Agreed. But these are inherent risks faced by every company.

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Agreed. But these are inherent risks faced by every company.

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News